iRegene Receives IND Approval from U.S. FDA to Start Clinical Trial for Parkinson’s Disease
iRegene Therapeutics has achieved a significant milestone with the U.S. Food and Drug Administration (FDA) granting Investigational New Drug (IND) approval for their innovative cell therapy, NouvNeu001, aimed at treating Parkinson’s disease. This approval marks a pivotal step forward in the fight against this debilitating neurodegenerative disorder. A New Hope for Parkinson’s Patients Parkinson’s disease, characterized by the loss of dopaminergic neurons, […]
Aspen Neuroscience Secures CIRM Grant for Groundbreaking Parkinson’s Disease Stem Cell Therapy
In a significant stride towards combating Parkinson’s disease, Aspen Neuroscience has been awarded a prestigious CLIN2 grant by the California Institute for Regenerative Medicine (CIRM). This milestone funding will accelerate the development of their innovative stem cell therapy, ANPD001. Aspen Neuroscience’s proprietary approach leverages cutting-edge induced pluripotent stem cells (iPSCs) to create personalized therapies aimed […]
Revolutionizing Parkinson’s Disease Treatment: TreeFrog Therapeutics’ Leap Forward
In the ever-evolving field of regenerative medicine, a significant milestone is on the horizon, courtesy of TreeFrog Therapeutics. At the 23rd Congress of the Japanese Society for Regenerative Medicine (JSRM) in Niigata, Japan, a presentation by Maxime Feyeux, the Chief Scientific Officer and Co-founder of TreeFrog, has sparked excitement and hope. TreeFrog Therapeutics, a frontrunner […]
Aspen Neuroscience Cofounder Dr. Andrés Bratt-Leal Receives 2023 Biocom California Life Science Catalyst Award
Dr. Andrés Bratt-Leal, co-founder and Senior Vice President of Research and Development at Aspen Neuroscience, has been honored with the prestigious 2023 Biocom California Life Science Catalyst Award. This accolade, presented by Biocom California, recognizes the most inspiring and driven young minds in the California life sciences industry who are making significant contributions to human […]
Regenerative Medicine: Induced Pluripotent Stem Cells (iPSCs) Therapy in Neurological Disorder Treatment
In recent years, the scientific community has been abuzz with the potential of induced pluripotent stem cells (iPSCs) for treating a myriad of diseases, especially neurological disorders. The allure of iPSCs lies in their ability to morph into any cell type in the human body, a characteristic termed as pluripotency. This remarkable trait is achieved […]
FDA Grants Fast Track Designation to ANPD001 for Parkinson’s Disease Treatment
Aspen Neuroscience, a clinical development-stage company, recently announced a significant milestone in the fight against Parkinson’s disease (PD). The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ANPD001, an autologous (personalized) investigational cell therapy designed to treat Parkinson’s disease by replacing lost dopamine neurons. This designation aims to accelerate the development […]
BlueRock’s Phase I Study with Bemdaneprocel in Parkinson’s Disease Patients Achieves Main Goal
BlueRock Therapeutics, in collaboration with Bayer AG, recently announced the successful results of their Phase I clinical trial for bemdaneprocel (BRT-DA01), an innovative cellular therapy derived from stem cells, aimed at treating Parkinson’s disease. The findings were presented at the International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark. Key Highlights: Dr. Claire […]
Rune Labs and Aspen Neuroscience Collaborate on Parkinson’s Disease Study
Rune Labs, a leading precision neurology software and data platform company, has joined forces with Aspen Neuroscience Inc., a prominent autologous cell therapy biotechnology firm. The collaboration aims to leverage Rune Labs’ StriveStudy clinical development platform, enabling Aspen to gather real-time, longitudinal patient data remotely. The primary objective of this partnership is to utilize the […]
Aspen’s Breakthrough FDA-Cleared Parkinson’s Cell Therapy Unveiled
Aspen Neuroscience has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ANPD001, an autologous cell therapy designed to treat Parkinson’s Disease (PD) by replacing lost dopamine neurons. The clearance enables Aspen to initiate a first-in-patient Phase 1/2a clinical trial for individuals with moderate to severe […]
Unlocking the Brain’s Secret Weapon: The Power of Neural Stem Cells!
The Therapeutic Potential of Neural Stem Cells Imagine a construction site. The workers there are like cells in our body, each with a specific job to do. But among them, there are a few who are like the site managers, capable of taking on any role as needed. These are the stem cells, the body’s […]